abeonatherapeutics.com - ABEO Short-Term Debt to Capital

Abeona Therapeutics (ABEO) is developing gene therapies to combat rare dermatological pathologies, leveraging anti-dumping protection via FDA exclusives and the capacity of its own US-based manufacturing plant. This price chart illustrates the asset's dynamics, where the current figure stands at 0.12. A positive brand image and support from patient advocacy groups strengthen the company's position ahead of the primary drug's market launch.

The implementation of robotic synthesis systems for gene therapies requires significant capital expenditures for cleanroom automation. The ratio of short-term liabilities to equity measures the reliance of Abeona Therapeutics (ABEO) on short-term loans, assessing the risk of shareholder dilution. By analyzing the current short-term liabilities-to-equity trend on GURU.Markets, an investor can determine the liquidity level and credit burden. A decrease in this ratio confirms the financial stability and long-term investment attractiveness of the asset.